DeepMed Research

LIEBEL-FLARSHEIM COMPANY LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas

Phase 3

Completed

Conditions: Brain Tumor, Recurrent
Brain Tumor, Primary

Interventions: Drug: Elucirem
Drug: Dotarem

First Posted Date: 2023-09-28

Last Posted Date: 2025-05-06

Lead Sponsor: Guerbet

Target Recruit Count: 138

Registration Number: NCT06057168

Locations: 🇭🇺
Országos Idegtudományi Intézet - Neuroonkológiai és Intracraniá, Budapest, Hungary
🇭🇺
Semmelweis Egyetem - Neurologiai Klinika, Budapest, Hungary
🇭🇺
Debreceni Egyetem, Debrecen, Hungary

and more 8 locations

Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children

Phase 3

Completed

Conditions: Lesion in Body Region
CNS Lesion

Interventions: Drug: Gadopiclenol
Drug: Comparator

First Posted Date: 2023-08-24

Last Posted Date: 2025-05-20

Lead Sponsor: Guerbet

Target Recruit Count: 240

Registration Number: NCT06010173

Locations: 🇯🇵
Meitetsu Hospital, Aichi, Japan
🇯🇵
Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
🇯🇵
Nakamura Memorial Hospital, Hokkaido, Japan

and more 24 locations

Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age

Phase 2

Completed

Conditions: Central Nervous System Diseases
Pediatric Disorder
Body Indication

Interventions: Drug: Gadopiclenol

First Posted Date: 2022-10-21

Last Posted Date: 2025-03-28

Lead Sponsor: Guerbet

Target Recruit Count: 36

Registration Number: NCT05590884

Locations: 🇭🇺
Országos Idegtudományi Intézet, Budapest, Hungary
🇭🇺
Semmelweis Egyetem, Budapest, Hungary
🇵🇱
Szpital Uniwersytecki nr 1 im. dr Antoniego Jurasza, Bydgoszcz, Poland

and more 8 locations

Safety and Performance of Optivantage Multi-use When Injecting Contrast Media for Contrast Enhanced CT Examination

Not yet recruiting

Conditions: Patient Participation

First Posted Date: 2022-09-13

Last Posted Date: 2022-09-13

Lead Sponsor: Guerbet

Target Recruit Count: 100

Registration Number: NCT05537779

Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-up

Recruiting

Conditions: Oncology

First Posted Date: 2022-04-07

Last Posted Date: 2022-09-15

Lead Sponsor: Guerbet

Target Recruit Count: 50

Registration Number: NCT05316077

Locations: 🇦🇹
Univ.-Klinik für Radiologie, Graz, Austria
🇫🇷
CHU-Hôpital François Mitterrand, Dijon, France
🇨🇭
CHUV, Lausanne, Switzerland

Pharmacokinetics and Safety of Gadopiclenol in Japanese Healthy Volunteers

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Placebo
Drug: gadopiclenol

First Posted Date: 2021-05-28

Last Posted Date: 2021-10-07

Lead Sponsor: Guerbet

Target Recruit Count: 27

Registration Number: NCT04906005

Locations: 🇯🇵
Hataka clinic, Fukuoka, Japan

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Phase 4

Recruiting

Conditions: Motor Function
Cognitive Function
Contrast Media

Interventions: Procedure: Motor Tests
Procedure: Cognitive Tests
Procedure: Unenhanced-MRI of the brain
Procedure: Gadolinium Measurements
Drug: Gadoterate meglumine
Drug: Gadoxetate disodium
Drug: Gadobenate dimeglumine
Drug: Gadobutrol
Drug: Gadodiamide
Drug: Gadoteridol

First Posted Date: 2020-05-04

Last Posted Date: 2024-05-17

Lead Sponsor: Guerbet

Target Recruit Count: 2076

Registration Number: NCT04373564

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇧🇷
Hospital Santa Marta, Taguatinga, Distrito Federal, Brazil

and more 43 locations

Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Phase 3

Completed

Conditions: CNS Lesion
Blood Brain Barrier Defect

Interventions: Drug: gadopiclenol
Drug: Gadobutrol 1Mmol/mL Solution for Injection Vial

First Posted Date: 2019-06-24

Last Posted Date: 2021-07-02

Lead Sponsor: Guerbet

Target Recruit Count: 260

Registration Number: NCT03996447

Locations: 🇧🇪
UZ Brussel - Campus Jette, Brussel, Belgium
🇺🇸
South Carolina Clinical & Translational Research (SCTR) Institute, Charleston, South Carolina, United States
🇭🇺
Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary

and more 30 locations

Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

Phase 3

Completed

Conditions: Lesion in Body Region

Interventions: Drug: gadopiclenol
Drug: Gadobutrol 1 MMOLE/ML Intravenous Solution

First Posted Date: 2019-06-14

Last Posted Date: 2021-11-10

Lead Sponsor: Guerbet

Target Recruit Count: 304

Registration Number: NCT03986138

Locations: 🇵🇱
Jagiellońskie Centrum Innowacji Sp. z o. o., Kraków, Poland
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
UT Health San Antonio, San Antonio, Texas, United States

and more 30 locations

Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI

Phase 2

Completed

Conditions: Pediatric Patients
Body Indication
Central Nervous System Indication

Interventions: Drug: P03277

First Posted Date: 2018-11-21

Last Posted Date: 2022-06-01

Lead Sponsor: Guerbet

Target Recruit Count: 80

Registration Number: NCT03749252

Locations: 🇧🇬
Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria
🇧🇬
MHAT Central Onco Hospital Ltd, Plovdiv, Bulgaria
🇧🇬
MHAT Dr. Stoyan Kirkovich, Stara Zagora, Bulgaria

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy